Bharat Biotech’s BBV154- Nasal Covid Vaccine Receives Approval For Phase 3 Clinical Trials

NEW DELHI: Vaccine Manufacturer Bharat Biotech’s Nasal Covid Vaccine, BBV154 has received approval to conduct Phase-3 clinical trials. BBV154 is an intranasal booster dose for people who have received both doses of Covaxin.

The Drug Controller General Of India today gave approval for the Phase-3 trials. The Trials will be conducted at nine locations in the country.

The Intra Nasal Vaccine as a booster will be easier to administer in mass immunization campaigns and help reduce or stop transmission.

According to Bharat Biotech, the nasal vaccine, BBV154 stimulates immune response at the site of infection and is very effective in blocking infection and transmission of COVID-19.

The Trials will be conducted at nine different sites by Bharat Biotech. Bharat Biotech had received regulatory approval for Mid-to late stage trials for its intranasal vaccine BBV154 in August last year.
The company submitted the late-stage application to the Drugs Controller General Of India in December 2021 stating that an intranasal vaccine as a booster dose will be easier to administer in mass vaccination campaigns.